Press release
United States Prescription Dermatological Drugs Market Set to Expand Rapidly by 2033 | Leading Companies in 2025 - Johnson & Johnson Inc, Astellas Pharma, Inc, Biofrontera AG, Dermira, Inc., Glaxosmithkline Plc, and Mylan N.V.
Prescription Dermatological Drugs Market
Psoriasis affects 1.5-5% of people in highly developed countries. Atopic dermatitis (AD), the most common chronic inflammatory skin condition, impacts 15-20% of children and 1-3% of adults globally. According to the NIH, acne ranks as the eighth most prevalent disease worldwide, affecting 9.4% of the population.
The company utilized its funding to advance its lead molecule, VB 1953, into Phase II studies for moderate to severe acne and to support operations. Numerous institutes and organizations are investing in dermatology-related projects. The National Institutes of Health (NIH) has awarded significant funding to dermatology research across multiple institutions, with support increasing from USD 104.4 million to USD 119.9 million, reflecting a growth rate of 14.7%.
In the US, acne vulgaris affects 80% of people, with severe cases causing lasting physical and mental scars in 20%. Atopic dermatitis is influenced by urban living, higher socioeconomic status, and family history, with prevalence at 7-8% in parts of Europe.
Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/prescription-dermatological-drugs-market?kb
Latest FDA Approvals
ZORYVE cream 0.05% received its sixth FDA approval in three years, now indicated for mild to moderate atopic dermatitis in young children; backed by the INTEGUMENT-PED Phase 3 trial.
Delgocitinib (Anzupgo; LEO Pharma) was FDA-approved in July 2025 for moderate to severe chronic hand eczema, opening a new therapeutic class in topical Janus kinase inhibitors.
Tapinarof cream, 1%, was approved for atopic dermatitis in patients 2+, with clinical trial data showing high rates of disease clearance at week 8.
Cemiplimab (Libtayo) was approved on October 9, 2025, to prevent recurrence of certain skin cancers after surgery and radiation.
Roflumilast foam 0.3% (ZORYVE) set for FDA decision on May 22, 2025, for scalp and body psoriasis
Key Players:
Johnson & Johnson Inc., Merck & Co., Inc., Bayer AG, Pfizer, F. Hoffmann-La Roche, Allergan, Abbvie, Inc, Astellas Pharma, Inc, Biofrontera AG, Bristol-Myers Squibb, Dermira, Inc., Glaxosmithkline Plc, and Mylan N.V.
Latest Product Launches
Arcutis Biotherapeutics launched ZORYVE (roflumilast) cream 0.05% for mild to moderate atopic dermatitis in children ages 2-5, offering a once-daily, steroid-free alternative and expanding the ZORYVE franchise; commercial availability starts end-October 2025.
EmrosiTM (minocycline hydrochloride) extended-release capsules, 40mg, were launched for treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Novartis's Cosentyx (secukinumab) continues as a blockbuster biologic for psoriasis, psoriatic arthritis, and other indications, with expanded US launches for hidradenitis suppurativa and an intravenous version.
Growth Forecast Projected:
The Global Prescription Dermatological Drugs Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
Research Process:
Both primary and secondary data sources have been used in the global Prescription Dermatological Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=prescription-dermatological-drugs-market
Key Segments:
By Product Type: ( Acne & Rosacea Drugs, Anti-Aging Drugs, Dermatitis & Seborrhea Drugs, Hair Loss & Hair Removal Drugs, Psoriasis Drugs, Skin Cancer Drugs, Others)
By Route of Administration: (Topical, Oral, Parenteral, Others)
By Distribution Channel: (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
Regional Analysis for Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Benefits of the Report:
Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.
Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.
Chapter 3: Offers an in-depth look at the competitive landscape among Prescription Dermatological Drugs producers, including revenue shares, strategic moves, and recent mergers and acquisitions.
Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.
Chapters 5 & 6: Analyze Prescription Dermatological Drugs revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.
Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.
Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.
Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.
Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.
Get Customization in the report as per your requirements: https://datamintelligence.com/customize/prescription-dermatological-drugs-market?kb
FAQ's
Q1: How fast is the Prescription Dermatological Drugs Market growing?
A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 6.20% from 2025 to 2032
Q2: Which regions are dominating the Prescription Dermatological Drugs Market and which are fastest-growing?
A: North America dominating the Prescription Dermatological Drugs market.
Have any Query @ https://www.datamintelligence.com/enquiry/prescription-dermatological-drugs-market?kb
Latest News
Market growth in the sector is accelerating, bolstered by increasing prevalence of skin disorders, advanced biologics, oral and topical alternatives, and wider access to innovative treatments.
FDA approvals are expanding options for patients with skin of color and younger children, underscoring equity and innovation priorities in dermatological care.
Journey Medical Corporation continues to expand its portfolio, now marketing eight branded FDA-approved prescription drugs for common skin conditions.
Notable drug launches and expanded indications are creating new gold standards in therapy for psoriasis, eczema, atopic dermatitis, and post-surgical cancer recurrence.
The sector's momentum is driven by rapid innovation in biologics, topical agents, and extended-release therapies-supported by robust investment and frequent FDA endorsements in 2025.
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States Prescription Dermatological Drugs Market Set to Expand Rapidly by 2033 | Leading Companies in 2025 - Johnson & Johnson Inc, Astellas Pharma, Inc, Biofrontera AG, Dermira, Inc., Glaxosmithkline Plc, and Mylan N.V. here
News-ID: 4215173 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
United States Infusion Therapy Market Booming with $73.7B By 2032 Growth Potenti …
DataM Intelligence has published a new research report on "Infusion Therapy Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Sample PDF Of This Report (Get…
United States Testing, Inspection and Certification (TIC) Industry Set for Massi …
Testing, Inspection and Certification Market size reached US$ 403.09 billion in 2024 and is expected to reach US$ 547.01 billion by 2032, growing with a CAGR of 3.89% during the forecast period 2025-2032.
DataM Intelligence has published a new research report on "Testing inspection and Certification Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key…
United States Solar Vehicle Industry Sector Growth Forecast to hit $5.9B by 2032 …
Solar Vehicle Market reached US$0.34 billion in 2024 and is expected to reach US$5.9 billion by 2032, growing with a CAGR of 43.15% during the forecast period 2025-2032.
DataM Intelligence has published a new research report on "Solar Vehicle Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this…
United States Multi-Factor Authentication (MFA) Market is Poised to Skyrocket to …
DataM Intelligence unveils its latest report on the "Multi-Factor Authentication Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging opportunities that can guide businesses in seizing growth potential and crafting winning strategies. Packed with data-driven insights on current developments and future trends, this report is essential for companies aiming…
More Releases for Drugs
Generic Drugs Market Application Anti-Infective Drugs, Anti-Arthritis Drugs, Ant …
Generic drugs are the medications that are developed to be similar to a medicine that is already commercially available in the market with a brand name. The generic drug is similar to the medicine available in terms of dosage, safety and strength, mode of administration, quality and intended use. Due to the similarities, generic drugs are capable of treating various diseases. Generic drugs are most cost effective than the branded…
Cytotoxic Drugs Market Growing Demand for Antimetabolite Drugs
According to Precision Business Insights (PBI), the latest report, the cytotoxic drugs market is expected to be valued at USD 15,927.2 million in 2022 and is poised to grow at a significant CAGR of 2.2% over 2022-2028. The primary drivers of the expansion of the global cytotoxic drugs market include the increasing prevalence of cancer diseases, the increasing use and approval of cytotoxic drugs, and the increasing consumption of alcohol…
Global Antithrombotic Drugs Market | Global Antithrombotic Drugs Industry | Glob …
Antithrombotic drugs are special drugs that help to prevent the formation of thrombus or clot. These drugs are used to reduce the formation of blood clots by reducing the capability of body to form a blood clot. Antithrombotic drugs act by preventing the production of vitamin K in the liver. Anticoagulant, antiplatelet, and thrombolytic agents are different types of antithrombotic agents that act by different clotting processes. Arterial & venous…
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication…
Hepatitis Drugs Market by Therapeutics, Diagnostics, Patient, Drugs Policy
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market.
Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market
Among the various types, the hepatitis C segment is expected to be the largest segment, and expected to witness the fastest…
Epilepsy Drugs Market by Country, Drugs, Company & Forecast
For More Information:
https://renub-research.blogspot.com/2019/04/the-factors-that-are-driving-global.html
Epilepsy is a chronic disease in which patient’s brain activities become abnormal due to seizures. Seizure is an unexpected rush of electrical activity in the brain. Seizure is categorized by two types - generalized seizures and focal or partial seizures. Generalized seizures affect the whole brain whereas focal or partial seizures affect just one part of the brain. Global epilepsy drugs market is expected to cross US$…
